. [eighty two] to assess the efficacy, basic safety and tolerability of Cannabidiol as an adjunct therapy in conjunction with anti-epileptic medicine to the patients struggling from tuberous sclerosis complex whose most frequent neurological symptom is epilepsy. On this clinical demo research, f